Bawei Shenqi Pill in the Treatment of Ankylosing Spondylitis

• Status: Recruiting
• Trial end date: 2020-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Bawei Shenqi Pill is effective in the treatment of active ankylosing spondylitis (AS).

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai University of Traditional Chinese Medicine
• Treatments: Meloxicam

Criteria

Inclusion Criteria:

• Compliance with New York standards revised in 1984

• Syndrome differentiation of traditional Chinese medicine for deficiency of kidney-yang

• 18 to 70 years of age, male and female

• Being able to understand or sign an informed consent form

Exclusion Criteria:

• Other spondyloarthropathy that does not meet the diagnostic criteria of ankylosing spondylitis, and TCM syndrome differentiation does not belong to kidney-yang deficiency type.

• Age is out of range

• Do not agree to participate in this topic or can not participate in the whole process

• Complicated with other rheumatic diseases or other seronegative spondyloarthropathy.

• Pregnant, lactating women and patients with serious visceral diseases, mental disorders and severe extraarticular manifestations, such as heart, lung, liver, kidney or hematopoietic system.

• Have had myocardial infarction or stroke, congestive heart failure and active digestive tract ulcer patients.

• Those who had received other research drugs three months before screening.

• Inability or unwillingness to provide informed consent or failure to comply with test requirements.

• The researchers believe that it is not suitable for the owners of the study.